Medical Cannabis for Cancer Patients
What the evidence actually shows for cancer symptoms, treatment side effects, and the persistent claim that cannabis cures cancer.
Cannabis is genuinely useful for some cancer-related symptoms — chemo-induced nausea and appetite loss have the strongest support. It is not a proven cancer cure, despite what testimonials on social media claim. Preclinical (petri dish and mouse) data showing cannabinoids kill tumor cells has not translated into human clinical benefit yet. If you have cancer, cannabis can be a reasonable adjunct for symptoms — but talk to your oncologist about drug interactions, especially with immunotherapy.
Plain-language summary
Cannabis and cannabinoid medicines can help some cancer patients feel better. The clearest use is preventing nausea and vomiting from chemotherapy, where two synthetic THC-based drugs — dronabinol and nabilone — are FDA-approved and have been used for decades [1][2]. Cannabis may also help with pain, appetite, anxiety, and sleep, though the evidence is weaker and trials often contradict each other.
What cannabis has not been shown to do is cure cancer or shrink tumors in humans. Lab studies in cells and mice have shown cannabinoids can kill some cancer cells, but this has not translated to real-world tumor shrinkage in patients [3][4]. Anyone selling you 'Rick Simpson Oil' as a cure is selling folklore, not medicine.
This article is not medical advice. Cancer treatment decisions belong between you and your oncology team. Cannabis can interact with chemotherapy, immunotherapy, and other medications.
What probably works (moderate to strong evidence)
Chemotherapy-induced nausea and vomiting (CINV) [evidence:strong for synthetic cannabinoids; evidence:weak for smoked/inhaled cannabis]. A Cochrane review found cannabis-based medicines were more effective than placebo and roughly comparable to older antiemetics for CINV [1]. Dronabinol (Marinol) and nabilone (Cesamet) are FDA-approved for this indication, typically as second-line agents when standard antiemetics (5-HT3 antagonists like ondansetron) fail [2]. Modern antiemetic regimens have improved substantially, so cannabis-based drugs are less commonly the first choice than they were in the 1980s.
Appetite stimulation in HIV-associated wasting has stronger evidence than in cancer cachexia, but dronabinol is sometimes used off-label for cancer patients with poor appetite [2][5]. Effect sizes are modest.
What might work (weak or mixed evidence)
Cancer pain Weak / limited. Nabiximols (Sativex, a THC:CBD oromucosal spray) has been studied for opioid-refractory cancer pain. Early phase II trials were encouraging, but three large phase III trials failed to show a statistically significant benefit over placebo for the primary endpoint [6]. Some subgroups appeared to benefit. Overall: cannabis is not a reliable substitute for opioids in severe cancer pain, but may help some patients as an adjunct.
Cancer-related anxiety, insomnia, and mood Weak / limited. Most evidence is extrapolated from non-cancer populations or from observational surveys of cancer patients who self-report improvement [7]. Placebo effects in this space are substantial.
Cachexia (cancer-related wasting) Weak / limited. A trial comparing THC, THC+CBD extract, and placebo in advanced cancer patients found no significant improvement in appetite or quality of life over placebo [8].
What doesn't work or has no good evidence
Cannabis as a cancer cure or tumor-shrinking agent [evidence:none in humans]. This is the most important myth to address. Preclinical studies — cells in dishes, tumors in mice — have shown that THC and CBD can induce apoptosis (cell death) in various cancer cell lines [3]. This has led to a large ecosystem of online testimonials, 'Rick Simpson Oil' protocols, and YouTube videos claiming cures.
Human clinical trials do not support these claims. A small pilot study of intracranial THC in nine patients with recurrent glioblastoma in 2006 [9] and a phase 1b trial of nabiximols plus temozolomide in glioblastoma [10] have not produced evidence of a survival benefit that would justify using cannabis in place of standard oncologic treatment. Choosing cannabis over proven cancer treatment is associated with worse survival [11].
Curing specific cancers with specific ratios or strains No data. Claims like '1:1 CBD:THC cures breast cancer' or 'high-CBD oil dissolves tumors' are folklore. The indica vs sativa framing is not meaningful here either.
What we don't know
- Whether cannabinoids have any meaningful anti-tumor effect in humans at achievable doses, and if so, in which cancers.
- Optimal dose, ratio (THC:CBD), and route of administration for symptom control.
- Whether long-term cannabis use during cancer treatment affects recurrence or survival.
- Interaction with immunotherapy: An observational study suggested cannabis use during nivolumab therapy was associated with lower response rates [12]. This is not proof of causation but is concerning enough that many oncologists now advise caution.
- Interactions with specific chemotherapy agents metabolized by CYP3A4 and CYP2C9 (CBD is a known inhibitor of both) [13].
Comparison with standard treatments
For CINV: Modern regimens (5-HT3 antagonists like ondansetron + NK1 antagonists like aprepitant + dexamethasone) work well for most patients. Cannabinoids are typically reserved for breakthrough nausea or when standard drugs fail or are not tolerated [2].
For pain: Opioids remain the standard for moderate-to-severe cancer pain. Cannabis is an adjunct, not a replacement. Some patients report reduced opioid needs when adding cannabis, but randomized data supporting an opioid-sparing effect in cancer specifically is limited [6].
For appetite: Corticosteroids (short-term) and progestins like megestrol acetate have more evidence than cannabinoids for cancer cachexia, though all options are imperfect [5].
For anti-tumor treatment: There is no comparison. Cannabis is not a cancer treatment. Standard-of-care therapy (surgery, chemotherapy, radiation, immunotherapy, targeted agents) has years of trial data behind it.
Risks and practical considerations
- Drug interactions: CBD inhibits CYP3A4 and CYP2C9, which metabolize many chemotherapy drugs, warfarin, and others [13]. Dose adjustments or avoidance may be needed.
- Possible reduced immunotherapy efficacy Weak / limited: One observational study suggested lower response to checkpoint inhibitors in cannabis users [12]. Discuss with your oncologist before combining.
- Contamination: Illicit or unregulated cannabis may contain pesticides, heavy metals, or microbial contamination — especially concerning in immunocompromised patients. Aspergillus contamination has caused fatal infections in cancer patients [14].
- Cognitive effects and falls, particularly in older patients on multiple sedating medications.
- Cost and legality vary widely; some jurisdictions have medical cannabis programs specifically for cancer patients.
- Cannabis hyperemesis syndrome: paradoxical worsening of nausea with heavy chronic use — easily mistaken for chemo side effects.
If you are considering cannabis during cancer treatment, tell your oncologist. Not to get permission, but because they need to know for interaction management and treatment monitoring.
Not medical advice
This article summarizes published evidence as of its writing. It is not a substitute for care from a qualified oncology team. Do not stop, delay, or replace cancer treatment based on anything you read on the internet — including this page. Cannabis and cannabinoid medicines have real uses in supportive oncology care, but they work best as part of a plan your medical team knows about.
Sources
- Peer-reviewed Smith LA, Azariah F, Lavender VT, Stoner NS, Bettiol S. Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. Cochrane Database of Systematic Reviews, 2015, Issue 11.
- Government National Cancer Institute (US). Cannabis and Cannabinoids (PDQ®) – Health Professional Version. Updated 2024.
- Peer-reviewed Velasco G, Sánchez C, Guzmán M. Anticancer mechanisms of cannabinoids. Current Oncology, 2016;23(S2):S23-S32.
- Peer-reviewed Abrams DI. The therapeutic effects of Cannabis and cannabinoids: An update from the National Academies of Sciences, Engineering and Medicine report. European Journal of Internal Medicine, 2018;49:7-11.
- Peer-reviewed Ruiz-García V, López-Briz E, Carbonell-Sanchis R, et al. Megestrol acetate for cachexia-anorexia syndrome. A systematic review. Journal of Cachexia, Sarcopenia and Muscle, 2018;9(3):444-452.
- Peer-reviewed Fallon MT, Albert Lux E, McQuade R, et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. British Journal of Pain, 2017;11(3):119-133.
- Peer-reviewed Pergam SA, Woodfield MC, Lee CM, et al. Cannabis use among patients at a comprehensive cancer center in a state with legalized medicinal and recreational use. Cancer, 2017;123(22):4488-4497.
- Peer-reviewed Strasser F, Luftner D, Possinger K, et al. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome. Journal of Clinical Oncology, 2006;24(21):3394-3400.
- Peer-reviewed Guzmán M, Duarte MJ, Blázquez C, et al. A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. British Journal of Cancer, 2006;95(2):197-203.
- Peer-reviewed Twelves C, Sabel M, Checketts D, et al. A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma. British Journal of Cancer, 2021;124:1379-1387.
- Peer-reviewed Johnson SB, Park HS, Gross CP, Yu JB. Use of Alternative Medicine for Cancer and Its Impact on Survival. Journal of the National Cancer Institute, 2018;110(1):121-124.
- Peer-reviewed Taha T, Meiri D, Talhamy S, Wollner M, Peer A, Bar-Sela G. Cannabis Impacts Tumor Response Rate to Nivolumab in Patients with Advanced Malignancies. The Oncologist, 2019;24(4):549-554.
- Peer-reviewed Brown JD, Winterstein AG. Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use. Journal of Clinical Medicine, 2019;8(7):989.
- Peer-reviewed Ruchlemer R, Amit-Kohn M, Raveh D, Hanuš L. Inhaled medicinal cannabis and the immunocompromised patient. Supportive Care in Cancer, 2015;23(3):819-822.
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.
Related
- Cannabis Hyperemesis Syndrome (CHS) — A paradoxical syndrome of cyclic vomiting in chronic cannabis users that resolves only wit...
- Nabilone — Nabilone is not a terpene — it is a synthetic THC analog prescription drug, and this artic...